<! -- Pour avoir les accordéons fermés par défaut -->

Team 1 – Signaling in environmental and drug toxicology

© all rights reserved

The Team 1 Signaling in environmental and drug toxicology is composed by three groups with their own specificities.

Meet Our Specialised Teams

Experimental Toxicology

System Toxicology

Genomic Epidemiology of Multifactorial DiseaseS

METATOX (Experimental toxicology)

Our team identifies the mechanisms of action activated by a variety of environmental pollutants, alone or in combination, to understand their influence on the incidence of various pathologies (cancer, liver diseases, neurodegenerative diseases) in order to identify biomarkers. We use and develop cellular, animal and computational models over several main lines of research:

1) Contextual studies to study the sensitizing effects of persistent organic pollutants such as Seveso dioxin on the development of liver fibrosis or demyelination in the central nervous system. We use rodent models and more recently the nematode C. elegans.

2) We are also developing innovative cell models to study, for example, the influence of adipocytes on tumor metabolic phenotype or the effect of inflammatory cells on hepatocyte function.

3) We leverage our data produced in vivo and in vitro to develop computational models of system toxicology. We develop network biology and predictive toxicology models by integrating these data (into European or national projects) providing potential links between the exposure to environmental chemicals and adverse health outcomes.

Keywords: persistent organic pollutants; AhR; metabolic disruption; cancer; chronic liver diseases; computational models

Texte alternatif, pour accessibilité

Team & group leader

Group members

SYSTOX (System Toxicology)

Group leader

SysTox website

Group members

GEMS (Genomic Epidemiology of Multifactorial DiseaseS)

The GEMS group develops statistical methods and strategies in genomic epidemiology to identify genes and gene-exposome interactions involved in multifactorial diseases (asthma, allergic diseases, melanoma). This research program integrates multi-omics data (genomics, epigenomics, transcriptomics, metabolomics) together with biological knowledge, through pathway and network analyses, to provide further insight into the molecular mechanisms involved in the disease process.

Keywwords: Genome-wide association studies, gene-environment interactions, statistical genetics, software development, integration of omics, asthma, allergic diseases, melanoma

Group leader

Group members

Job offers

  • Assistant Ingénieur/Ingénieur d’Etudes, Immunotoxicité In-vitro/In-vivo. Poste d’une durée 2 ans à pourvoir immédiatement (avril-mai 2023) : profil

Main publications

  • Multiple basal cell carcinomas revealing a biallelic MUTYH gene mutation in a 39-year-old male patient.Tzoumpa S, Sevenet N, Bejar-Ardiles CL, Villette B, Zumelzu C, Benamouzig R, Caux F, Maubec E J Eur Acad Dermatol Venereol
  • Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Brunet-Possenti F, De Quatrebarbes J, Grob JJ, Saiag P, Maubec E, Stoebner PE, Granel-Brocard F, Arnault JP, Allayous C, Oriano B, Lebbe C, Montaudié H J Am Acad Dermatol
  • Application of AOPs to assist regulatory assessment of chemical risks – Case studies, needs and recommendations.Bajard L, Adamovsky O, Audouze K, Baken K, Barouki R, Beltman JB, Beronius A, Bonefeld-Jørgensen EC, Cano-Sancho G, de Baat ML, Di Tillio F, Fernández MF, FitzGerald RE, Gundacker C, Hernández AF, Hilscherova K, Karakitsios S, Kuchovska E, Long M, Luijten M, Majid S, Marx-Stoelting P, Mustieles V, Negi CK, Sarigiannis D, Scholz S, Sovadinova I, Stierum R, Tanabe S, Tollefsen KE, van den Brand AD, Vogs C, Wielsøe M, Wittwehr C, Blaha L Environ Res
  • Impact of mixtures of persistent organic pollutants on breast cancer aggressiveness.Benoit L, Koual M, Tomkiewicz C, Bats AS, Antignac JP, Coumoul X, Barouki R, Cano-Sancho G Environ Int
  • Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L Eur J Cancer
  • Application of artificial intelligence to decode the relationships between smell, olfactory receptors and small molecules.Achebouche R, Tromelin A, Audouze K, Taboureau O Sci Rep
    • See all publications